Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Lymphoma, Follicular 7Lymphoma 7Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell, Marginal Zone 3Leukemia, Lymphocytic, Chronic, B-Cell 3Waldenstrom Macroglobulinemia 2Lymphoma, B-Cell 2Burkitt Lymphoma 2Recurrence 1Neoplasms by Histologic Type 1Neoplasms 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lymphoma, Mantle-Cell 1Lymphatic Diseases 1Immunoproliferative Disorders 1Immune System Diseases 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Dexamethasone 112Bortezomib 61Lenalidomide 49Cyclophosphamide 49Calcium Dobesilate 43pomalidomide 32Melphalan 31fludarabine 25Filgrastim 25carfilzomib 22fludarabine phosphate 21daratumumab 20Granulocyte Colony-Stimulating Factor 16Whole-Body Irradiation 15Antilymphocyte Serum 15dexamethasone acetate 14Mycophenolic Acid 14Thalidomide 13Tacrolimus 13Cyclosporine 13Busulfan 13Peripheral Blood Stem Cell Transplantation 12ixazomib 11dexamethasone 21-phosphate 10auricularum 10pembrolizumab 9Radiotherapy 9Etoposide 9belantamab mafodotin 8Rituximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Multiple Myeloma × ibritumomab tiuxetan × Clear all
NCT01207765 2017-03-20

Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma

Tufts Medical Center

Phase 2 Terminated
8 enrolled 8 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡